Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study

T Sonia Boender1, Kim C E Sigaloff, Joshua Kayiwa

  • 1PharmAccess Foundation, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

Insights

Most children with HIV in Uganda present late for treatment. Factors like young age, caregiver unemployment, and lack of HIV prevention during birth contribute to delayed care, requiring multifaceted interventions.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Early diagnosis and treatment of HIV in children are crucial for better outcomes.
  • Resource-limited settings often face challenges with late presentation of pediatric HIV cases.

Purpose of the Study:

  • To identify factors associated with delayed treatment initiation in HIV-infected children in Uganda.
  • To explore caregiver and health worker perspectives on barriers to timely HIV care.

Main Methods:

  • Multilevel logistic regression analysis of clinical and demographic data from 306 children.
  • Semistructured interviews with 49 caregivers and health workers to gather qualitative insights.

Main Results:

  • 72% of children presented with late-stage HIV (WHO stages 3-4).
  • Key risk factors included young age (<2 years), living without parents, caregiver unemployment, lack of perinatal HIV prophylaxis, and high transportation costs.
  • Qualitative data highlighted inconsistent referrals, caregiver unawareness, fear, and stigma as additional barriers.

Conclusions:

  • Late presentation of pediatric HIV in Uganda is a significant issue driven by complex health system and individual-level factors.
  • Addressing these multifactorial determinants is essential for improving early diagnosis and treatment initiation for children living with HIV.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...